Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
Tweet Send to a Friend
Goldman Sachs analyst Asad Haider reiterated a Neutral rating and $26.00 price target on Pfizer (NYSE: PFE).The analyst comments "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
